APOA1 and Alzheimer disease: Emerging evidence strongly supports the association between ApoAI and ApoE, key components of HDL particles in the periphery and CNS, with AD pathophysiology and clinical outcomes, suggesting a potential value of predicting and monitoring disease progression for HDL‐Apos.